Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
University of Kentucky Medical Center, Lexington, Kentucky New York Presbyterian Hospital-Columbia University Medical Center, New York, New York